2. Search Result
Search Result
Pathways Recommended: NF-κB MAPK/ERK Pathway Neuronal Signaling JAK/STAT Signaling
Results for "

IRF and NF-κB pathway signaling

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-173063
    TLR8 antagonist-1

    		Toll-like Receptor (TLR) NF-κB MyD88 Inflammation/Immunology
    TLR8 antagonist-1 (Compound 10) is a selective TLR8 antagonist. TLR8 antagonist-1 can inhibit TLR8-mediated inflammation and signaling pathways, reduce the recruitment of MyD88, and inhibit the NF-κB and IRF pathways. TLR8 antagonist-1 has anti-inflammatory activity .
    TLR8 antagonist-1
  • HY-117066
    CL075
    3 Publications Verification

    3M002

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively .
    CL075
  • HY-149724
    Anti-inflammatory agent 65

    		STING NO Synthase Inflammation/Immunology
    Anti-inflammatory agent 65 (compound 29) is a Hederagonic acid derivative with potent anti-inflammatory activity. Anti-inflammatory agent 65 inhibits nitric oxide (NO) release. Anti-inflammatory agent 65 inhibits the nuclear translocation of IRF3 and p65, and disrupts the STING/IRF3/NF-κB signaling pathway, thereby attenuating the inflammatory response .
    Anti-inflammatory agent 65
  • HY-112880
    c-(2'FdAMP-2'FdIMP)

    		Drug Derivative STING NF-κB IFNAR Interleukin Related Infection Cancer
    c-(2'FdAMP-2'FdIMP) (Compound 52),a derivative of cAIMP (HY-134375), is a cyclic dinucleotide (CDN). c-(2'FdAMP-2'FdIMP) is a STING activator and significantly induce STING-dependent IRF and NF-κB pathway signaling. c-(2'FdAMP-2'FdIMP) can be used for STING-based immunotherapy, such as cancers and infectious diseases research .
    c-(2'FdAMP-2'FdIMP)
  • HY-176192
    SMU-14a

    		Toll-like Receptor (TLR) TNF Receptor NF-κB p38 MAPK ERK IKK Inflammation/Immunology
    SMU-14a is a TLR3 inhibitor (IC50: 0.18 µM). SMU-14a inhibits IL-6 secretion in mouse peritoneal macrophages and downregulates TNF-α in human peripheral blood monocytes. SMU-14a exerts anti-inflammatory effects by reducing the phosphorylation of p65, ERK, and TBK1 through NF-κB, MAPK, and IRF3 signaling pathways, and decreasing serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. SMU-14a can be used in the study of acute hepatitis .
    SMU-14a

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: